Third Point’s BioMarin Pharmaceuticals BMRN Stock Holding History

Third Point’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-385,000	Closed	-$37.1M	–	41
2023 Q4	$37.1M	Buy	+385,000	New	+$34.1M	0.56%	26

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Third Point's BMRN Position: Q1 2024 in Review

Third Point sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 385,000 shares — an estimated $37.1M sold.

Third Point first reported a position in BMRN in Q4 2023 and held it in 1 quarter. The position peaked at $37.1M in Q4 2023. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

Third Point reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Third Point sold 385,000 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $37.1M.
Third Point first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 1 quarter.
Third Point's BioMarin Pharmaceuticals position peaked at $37.1M in Q4 2023.
560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Third Point's 13F filing for Q1 2024, filed 15 May 2024.